Key result
In pediatric heart transplant recipients randomized to tacrolimus or cyclosporine, cardiac apoptosis indices correlated negatively with F2α isoprostanes at Week 2 (r = -0.88).
Why the study?
Does tacrolimus compared to cyclosporine affect biomarker and subcellular myocardial changes in pediatric heart transplant recipients?
RCT (n=11)
Open-label
parallel group
Does tacrolimus compared to cyclosporine affect biomarker and subcellular myocardial changes in pediatric heart transplant recipients?
Systemic and myocardial oxidative damage and inflammation occur early post-pediatric heart transplant and may relate to cardiac remodeling.
Early apoptosis-isoprostane interplay may guide post-transplant remodeling surveillance; extends mechanistic insights in pediatric RCT data.
Cardiac remodeling is associated with plasma biomarkers of fibrinogenesis, inflammation, and oxidative stress, and upregulation of mitogenic, pro-fibrotic, and apoptotic signaling pathways. Our primary objective was to evaluate biomarker and subcellular myocardial changes in pediatric heart transplant recipients. Fifty-two-week prospective, randomized (tacrolimus, Tac, vs. cyclosporine, CsA), open-label, parallel group study. Serial myocardial biopsies were probed for mitogenic and pro-inflammatory proteins. Plasma biomarkers of oxidative stress (F2α isoprostanes, nitrotyrosine), and inflammation and oxidation (hsCRP and cystatin-C) were measured. Nine of 11 randomized patients completed the study (four Tac, five CsA). Mean levels of F2α isoprostanes, hsCRP, and cystatin-C were maximal at Week 2. Peak activation of all MAP kinases in myocardial tissue was maximal at Week 10; no association was seen with rejection. Cardiac Bax/Bcl-2 levels (index of apoptosis) correlated negatively with F2α isoprostanes at Week 2 (r = -0.88) and with hsCRP at Week 52 (r = -0.67). At Week 52, hsCRP levels correlated positively with molecular indices of cardiac cell growth. We found evidence of systemic and myocardial oxidative damage and inflammation early posttransplant, which may be related to the remodeling process. Further study is needed to better understand the cardiac and systemic repair processes following pediatric heart transplantation.
No takes yet. Share an insight, caveat, or question.
Dipchand et al. (2014) conducted an RCT in pediatric heart transplantation (n=11). Tacrolimus vs. Cyclosporine was evaluated on Biomarker and subcellular myocardial changes. In pediatric heart transplant recipients randomized to tacrolimus or cyclosporine, cardiac apoptosis indices correlated negatively with F2α isoprostanes at Week 2 (r = -0.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: